癌性贫血是单因素或多因素共同作用的结果,这些因素包括慢性病贫血、肿瘤引起的出血、溶血、骨髓浸润、营养不良、放化疗引起的骨髓抑制等。由于全球老龄化趋势及各种致癌相关因素的存在,导致恶性肿瘤的发病率持续升高,癌性贫血更为凸显。既往欧洲癌症贫血调查(european cancer anemia survey,ECAS)显示肿瘤患者贫血发病率为39.3%(Hb<120g/L)[1],近年国外一个癌症贫血调查显示肿瘤相关性贫血发病率为49%(Hb<120g/L)[2],重组人促红细胞生成素(recombinant human erythropoietin,rhEPO)治疗肿瘤相关性贫 Cancerous anemia is the result of single or multiple factors including anemia of chronic disease, tumor-induced bleeding, hemolysis, bone marrow infiltration, malnutrition, and bone marrow suppression caused by chemoradiation. Due to the global aging trend and the existence of various carcinogenic related factors, the incidence of malignant tumors continues to rise, with cancerous anemia more prominent. In the past, the European anemia anemia survey (ECAS) showed that the incidence of anemia in cancer patients was 39.3% (Hb <120g / L) [1]. In recent years, a survey of anemia of aneurysm abroad showed that the incidence of anemia associated with anemia was 49% Hb <120g / L) [2], recombinant human erythropoietin (rhEPO) treatment of tumor-related lean